Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.85 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.85 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8364772 | 1.00 | CTSB (0.85) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL11947501 | 0.93 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL222429 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL227410 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL31554839 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL24058604 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL15462595 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL13556415 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL7736941 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL19246297 | 0.92 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120101049-A1 | Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20110160149-A1 | Pharmaceutical Composition for a Hepatitis C Viral Protease Inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-30 | — | — | US | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | CTSB 214/4885PPP3CB 29/4885ABCC1 646/4885 |
| US-20110160149-A1 | Pharmaceutical Composition for a Hepatitis C Viral Protease Inhibitor | LIPC, HPN, CEL | CTSB 63/4885PPP3CB 789/4885ABCC1 730/4885 |
| US-20120101049-A1 | Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration | HAVCR2, LIPC, SLC10A1 | CTSB 497/4885PPP3CB 81/4885ABCC1 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.